127 related articles for article (PubMed ID: 19485887)
1. Do adenosine receptors offer new therapeutic options for diabetic nephropathy?
San Martín R; Valladares D; Roa H; Troncoso E; Sobrevia L
Curr Vasc Pharmacol; 2009 Oct; 7(4):450-9. PubMed ID: 19485887
[TBL] [Abstract][Full Text] [Related]
2. The effects of adenosine A2B receptor inhibition on VEGF and nitric oxide axis-mediated renal function in diabetic nephropathy.
Patel L; Thaker A
Ren Fail; 2014 Jul; 36(6):916-24. PubMed ID: 24678970
[TBL] [Abstract][Full Text] [Related]
3. Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.
Carranza K; Veron D; Cercado A; Bautista N; Pozo W; Tufro A; Veron D
Nefrologia; 2015; 35(2):131-8. PubMed ID: 26300505
[TBL] [Abstract][Full Text] [Related]
4. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
Nakagawa T; Sato W; Glushakova O; Heinig M; Clarke T; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Johnson RJ; Croker B
J Am Soc Nephrol; 2007 Feb; 18(2):539-50. PubMed ID: 17202420
[TBL] [Abstract][Full Text] [Related]
5. The renal endothelium in diabetic nephropathy.
Eleftheriadis T; Antoniadi G; Pissas G; Liakopoulos V; Stefanidis I
Ren Fail; 2013; 35(4):592-9. PubMed ID: 23472883
[TBL] [Abstract][Full Text] [Related]
6. Imbalance of glomerular VEGF-NO axis in diabetic rats: prevention by chronic therapy with propyl gallate.
Tian S; Gan Y; Li J; Wang L; Shen J; Liu T; Ye T; Liu H; Liu D; Deng Y; Wang W
J Nephrol; 2011; 24(4):499-506. PubMed ID: 21425119
[TBL] [Abstract][Full Text] [Related]
7. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy.
Nakagawa T; Sato W; Kosugi T; Johnson RJ
J Diabetes Res; 2013; 2013():184539. PubMed ID: 24386643
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and diabetic nephropathy.
Chen S; Ziyadeh FN
Curr Diab Rep; 2008 Dec; 8(6):470-6. PubMed ID: 18990304
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A
Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.
Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H
Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390
[TBL] [Abstract][Full Text] [Related]
11. Adenosine receptors: new therapeutic targets for inflammation in diabetic nephropathy.
Elsherbiny NM; Al-Gayyar MM
Inflamm Allergy Drug Targets; 2013 Jun; 12(3):153-61. PubMed ID: 23621447
[TBL] [Abstract][Full Text] [Related]
12. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
13. Finasteride reduces microvessel density and expression of vascular endothelial growth factor in renal tissue of diabetic rats.
Tian HL; Zhao CX; Wu HY; Xu ZX; Wei LS; Zhao RT; Jin DL
Am J Med Sci; 2015 Jun; 349(6):516-20. PubMed ID: 25789687
[TBL] [Abstract][Full Text] [Related]
14. VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment?
Dei Cas A; Gnudi L
Metabolism; 2012 Dec; 61(12):1666-73. PubMed ID: 22554833
[TBL] [Abstract][Full Text] [Related]
15. The endothelium in diabetic nephropathy.
Advani A; Gilbert RE
Semin Nephrol; 2012 Mar; 32(2):199-207. PubMed ID: 22617769
[TBL] [Abstract][Full Text] [Related]
16. Targeting adenosine signaling to treatment of diabetic nephropathy.
Quezada C; Alarcón S; Jaramillo C; Muñoz D; Oyarzún C; San Martín R
Curr Drug Targets; 2013 Apr; 14(4):490-6. PubMed ID: 23316933
[TBL] [Abstract][Full Text] [Related]
17. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease.
Nakagawa T
Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1665-72. PubMed ID: 17545302
[TBL] [Abstract][Full Text] [Related]
18. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.
Hohenstein B; Hausknecht B; Boehmer K; Riess R; Brekken RA; Hugo CP
Kidney Int; 2006 May; 69(9):1654-61. PubMed ID: 16541023
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic Therapy for Diabetic Nephropathy.
Tanabe K; Maeshima Y; Sato Y; Wada J
Biomed Res Int; 2017; 2017():5724069. PubMed ID: 28835895
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy.
Sugimoto H; Shikata K; Matsuda M; Kushiro M; Hayashi Y; Hiragushi K; Wada J; Makino H
Diabetologia; 1998 Dec; 41(12):1426-34. PubMed ID: 9867209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
